Stroke
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
On Market (1)
Approved therapies currently available
Competitive Landscape
107 companies ranked by most advanced pipeline stage
+77 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 46,593 patients across 50 trials
Safety and Efficacy of the Tong-Fu-Xing-Shen Herbal Formula for Stroke-Associated Pneumonia
SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke
The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial
The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule
Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial
Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke
Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
EndoVascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke
Stroke Inpatient Rehabilitation Reinforcement of ACTivity
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
A RCT to Establish the Effectiveness of Intermittent Pneumatic Compression to Prevent Post Stroke DVT
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
Participative Rehabilitation in Stroke Patients
PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
Abciximab in Wake-up Stroke
Insulin Resistance Intervention After Stroke Trial
MLC1501 Study Assessing Efficacy in STROke Recovery
Maraviroc to Augment Rehabilitation Outcomes After Stroke
Regenerative Stem Cell Therapy for Stroke in Europe
Multicenter Rehabilitation Study in Acute Stroke
Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy
Study of ONO-2506 in Patients With Acute Ischemic Stroke
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke
Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue.
The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFO
Post-Stroke Optimization of Walking Using Explosive Resistance
Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
Safety of Intravenous Thrombolytics in Stroke on Awakening
Prehospital COOLing 1 (PreCOOL 1)
Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions
Pedaling Exercises for Disability and Activity Limitations
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
Evaluating Neuroprotection in Aneurysm Coiling Therapy
Study of NeuroAid In Enhancing Recovery After Stroke
Study to Assess the Safety and Effectiveness of the Penumbra System
Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
Shoulder, or Elbow, or Wrist: What Should we Train First After a Stroke?
Related Jobs in Neurology
Sr Commercial Excellence Manager, Stroke
Sr Software Engineer, User Facing Applications
Staff Manufacturing Engineer, Consumables
Executive Associate II, Neuroscience GPLs
Director, Program Management, Neuroscience
Senior Therapeutic Area Specialist, Neurology/MS – Orlando, FL
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.